Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer

doi:10.1002/mco2.498

PDF

MedComm ›› 2024, Vol. 5 ›› Issue (3) : e498. DOI: 10.1002/mco2.498

HIGHLIGHTS

Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer

Zhijun Yuan¹, Mengyuan Yang^2,³, Xian Zhong^2,³()

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Zhijun Yuan, Mengyuan Yang, Xian Zhong. Perioperative immunotherapy: the main clinical treatment for resectable non-small cell lung cancer. MedComm, 2024, 5(3): e498 https://doi.org/10.1002/mco2.498

References

1	H Wakelee, M Liberman, T Kato, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491-503.
2	S Saw, BH Ong, K Chua, A Takano, D Tan. Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol. 2021;22(11):e501-e516.
3	JD Spicer, S Gao, M Liberman, et al. LBA56 overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Ann Oncol. 2023(2):S1297-S1298.
4	JV Heymach, D Harpole, T Mitsudomi, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672-1684.
5	S Lu, L Wu, W Zhang, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024;331(3):201-211.